Opportunity Information: Apply for PAR 06 342
Apply for PAR 06 342
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Innovative Therapies and Clinical Studies for Screenable Disorders (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173 Research Related to Deafness and Communication Disorders 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Apr 10, 2006.
- Applicants must submit their applications by Jan 7, 2010 Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments Small businesses Special district governments County governments For profit organizations other than small businesses.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply. Faith based or community based organizations
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 06 342, titled Innovative Therapies and Clinical Studies for Screenable Disorders (R21), supports early-stage, exploratory research aimed at improving both the basic scientific understanding and the development of treatments for disorders that are already part of newborn screening programs, as well as certain high-priority genetic conditions that could realistically become screenable in the near future. The underlying idea is practical and policy-relevant: if a disorder can be identified early through screening, there needs to be a meaningful medical benefit to finding it early. For conditions not yet on screening panels, the FOA emphasizes that progress toward an effective therapy can be the key step that makes newborn screening worthwhile and justifiable. In this announcement, a "high priority condition" is defined specifically as a condition where the availability of an efficacious therapy would make it appropriate for newborn screening, meaning the therapy changes outcomes enough that early detection matters.
The opportunity is sponsored by three NIH Institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). That mix signals a broad range of potential topic areas, spanning pediatric and developmental health, communication and hearing-related disorders, and metabolic, endocrine, digestive, and kidney diseases. The scientific scope is intentionally flexible because the research needs across screenable disorders vary widely, from mechanistic work that clarifies disease pathways to preclinical therapeutic development and early clinical or translational studies that help move an intervention closer to real-world use.
This FOA uses the NIH Exploratory/Developmental Research Grant (R21) mechanism, which is generally intended for high-impact, early or pilot-stage projects where investigators are testing new approaches, generating preliminary data, or rapidly assessing feasibility. The announcement notes that award sizes and durations may vary depending on what is proposed, but it sets clear limits for the mechanism: projects may run no longer than two years, with direct costs capped at $275,000 total across the two-year period and no more than $200,000 in direct costs in any single year. As with many NIH programs, the number of awards and total dollars ultimately depend on the volume and quality of applications received, along with their requested budgets and proposed timelines.
A notable feature is that this R21 announcement runs in parallel with two other NIH announcements that cover the same scientific scope but use different grant mechanisms: an R03 for smaller, short projects and an R01 for more mature, fully developed research programs. This structure gives applicants options depending on how advanced their therapeutic concept is and how much work is needed to demonstrate readiness for larger-scale studies. In other words, the same basic mission is supported across three funding tracks, letting investigators align their application with the right level of risk, evidence, and project scale.
Eligibility is broad and includes both for-profit and non-profit organizations, public or private institutions, and a wide range of government and community entities. Eligible applicants include universities and colleges, hospitals, labs, state and local government units, eligible federal agencies, faith-based and community-based organizations, and tribal entities (including units of state and local tribal government). Foreign institutions are explicitly eligible to apply, which opens the door for international collaborations or research programs based outside the United States when the proposed work fits NIH priorities. The FOA also covers many organizational categories typically listed in federal opportunities, including small businesses, independent school districts, special district governments, and various nonprofit types (including 501(c)(3) and non-501(c)(3) organizations).
The FOA is open with respect to who can serve as Project Director/Principal Investigator (PD/PI), focusing on capability rather than career stage or background. Any individual with the skills, knowledge, and resources to carry out the project is invited to apply through their institution. NIH also reiterates its standing encouragement for individuals from underrepresented racial and ethnic groups and individuals with disabilities to apply for support. Applicants are allowed to submit more than one application as long as each submission is scientifically distinct, which is helpful for teams pursuing multiple therapeutic concepts or targeting different disorders with separate approaches.
Administratively, the opportunity is a discretionary grant under NIH, categorized in the health domain (Health, Income Security and Social Services), and tied to CFDA program areas that include deafness and communication disorders (93.173), diabetes/digestive/kidney diseases extramural research (93.847), and child health and human development extramural research (93.865). The opportunity originally posted in April 2006, used multiple receipt dates, and lists a final closing date in early January 2010, with archiving in February 2010. The full announcement and detailed requirements were provided through the NIH grants guide at the link included in the source information.
FAQs: NIH PAR-06-342 - Innovative Therapies and Clinical Studies for Screenable Disorders (R21)
What is PAR-06-342?
PAR-06-342 is an NIH funding opportunity titled "Innovative Therapies and Clinical Studies for Screenable Disorders (R21)". It supports early-stage, exploratory research intended to improve scientific understanding and advance treatments for certain disorders connected to newborn screening.
What is the main purpose of this funding opportunity?
The purpose is to support research that helps ensure early identification through newborn screening leads to meaningful medical benefit. For disorders already screened at birth, the program supports work that improves understanding and treatment. For conditions not yet on screening panels, it emphasizes that progress toward an effective therapy can be the key step that makes newborn screening worthwhile and justifiable.
What kinds of disorders are in scope?
The scope includes disorders that are already part of newborn screening programs and certain high-priority genetic conditions that could realistically become screenable in the near future.
How does this FOA define a "high priority condition"?
In this announcement, a "high priority condition" is specifically defined as a condition where the availability of an efficacious therapy would make it appropriate for newborn screening, meaning the therapy changes outcomes enough that early detection matters.
Which NIH Institutes sponsor this opportunity?
This FOA is sponsored by three NIH Institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What does the mix of sponsoring Institutes suggest about topic areas?
The sponsors signal a broad range of potential topic areas, spanning pediatric and developmental health, communication and hearing-related disorders, and metabolic, endocrine, digestive, and kidney diseases.
What is the scientific scope of the research supported?
The scientific scope is intentionally flexible. It can include mechanistic work that clarifies disease pathways, preclinical therapeutic development, and early clinical or translational studies that move an intervention closer to real-world use.
What grant mechanism does this FOA use?
This FOA uses the NIH Exploratory/Developmental Research Grant (R21) mechanism, which is generally intended for high-impact, early or pilot-stage projects where investigators test new approaches, generate preliminary data, or rapidly assess feasibility.
How long can an R21 project last under this FOA?
Projects may run no longer than two years.
What is the budget limit for this R21?
Direct costs are capped at $275,000 total across the two-year period, with no more than $200,000 in direct costs in any single year.
Do award sizes and durations ever vary?
The announcement notes that award sizes and durations may vary depending on what is proposed, but they must stay within the R21 limits described (no more than two years; direct cost caps apply).
How many awards will NIH make under this opportunity?
The number of awards and the total funding depend on the volume and quality of applications received, as well as requested budgets and proposed timelines.
Are there related funding opportunities with the same scientific scope?
Yes. This R21 announcement runs in parallel with two other NIH announcements that cover the same scientific scope but use different grant mechanisms: an R03 for smaller, short projects and an R01 for more mature, fully developed research programs.
Why does NIH offer R03, R21, and R01 options for the same mission?
This structure gives applicants options depending on how advanced their therapeutic concept is and how much work is needed to demonstrate readiness for larger-scale studies. It allows investigators to align the application with an appropriate level of risk, evidence, and project scale.
What types of organizations are eligible to apply?
Eligibility is broad and includes both for-profit and non-profit organizations, public or private institutions, and a wide range of government and community entities. Examples listed include universities and colleges, hospitals, laboratories, state and local government units, eligible federal agencies, faith-based and community-based organizations, and tribal entities (including units of state and local tribal government).
Are foreign institutions eligible to apply?
Yes. Foreign institutions are explicitly eligible to apply, allowing for international collaborations or research programs based outside the United States when the proposed work fits NIH priorities.
Are small businesses eligible?
Yes. The FOA includes small businesses among the organizational categories typically eligible under federal opportunities.
Who can serve as the Project Director/Principal Investigator (PD/PI)?
The FOA is open with respect to who can serve as PD/PI. Any individual with the skills, knowledge, and resources to carry out the project is invited to apply through their institution.
Does NIH encourage applications from underrepresented groups?
Yes. NIH reiterates its standing encouragement for individuals from underrepresented racial and ethnic groups and individuals with disabilities to apply for support.
Can an applicant submit more than one application?
Yes. Applicants may submit more than one application as long as each submission is scientifically distinct.
What federal program areas or CFDA numbers are associated with this opportunity?
This opportunity is tied to CFDA program areas including deafness and communication disorders (93.173), diabetes/digestive/kidney diseases extramural research (93.847), and child health and human development extramural research (93.865).
How is this opportunity categorized administratively?
It is described as a discretionary grant under NIH and categorized in the health domain (Health, Income Security and Social Services).
When was the opportunity posted and when did it close?
The opportunity originally posted in April 2006, used multiple receipt dates, lists a final closing date in early January 2010, and was archived in February 2010.
Where were the full announcement and detailed requirements provided?
The full announcement and detailed requirements were provided through the NIH grants guide at the link included in the source information.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Innovative Therapies and Clinical Studies for Screenable Disorders (R03)
Previous opportunity: Womens Mental Health and Sex/Gender Differences Research (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 06 342
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 06 342) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Therapies and Clinical Studies for Screenable Disorders (R03) Apply for PAR 06 341 Funding Number: PAR 06 341 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Shared Neurobiology of Fragile X Syndrome and Autism (R03) Apply for PA 06 429 Funding Number: PA 06 429 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Shared Neurobiology of Fragile X Syndrome and Autism (R21) Apply for PA 06 430 Funding Number: PA 06 430 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Educational Programs for Population Research (R25) Apply for PA 06 507 Funding Number: PA 06 507 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Transmission of Human Immunodeficiency Virus (HIV) In Semen (R01) Apply for PA 07 044 Funding Number: PA 07 044 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Collaborative Research for Molecular and Genomic Studies of Basic Behavior in Animal Models (R01) Apply for PA 07 096 Funding Number: PA 07 096 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Clinical Studies for Screenable Disorders (R01) Apply for PAR 07 184 Funding Number: PAR 07 184 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Vulvodynia Systematic Epidemiologic, Etiologic Or Therapeutic Studies (R01) Apply for PA 07 182 Funding Number: PA 07 182 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Eating Disorders (R01) Apply for PA 07 285 Funding Number: PA 07 285 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fragile X Pre mutation and Ovarian Function (R01) Apply for PA 07 219 Funding Number: PA 07 219 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fragile X Pre mutation and Ovarian Function (R03) Apply for PA 07 220 Funding Number: PA 07 220 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Multidisciplinary Translational Research in Critical Care (R01) Apply for PA 07 233 Funding Number: PA 07 233 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| International Extramural Associates Research Development Awards (IEARDA) (G11) Apply for PAR 07 431 Funding Number: PAR 07 431 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Interdisciplinary Research on Implantation (R01) Apply for PA 07 445 Funding Number: PA 07 445 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) Apply for PAR 07 446 Funding Number: PAR 07 446 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03) Apply for PAR 07 447 Funding Number: PAR 07 447 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R01) Apply for PA 08 059 Funding Number: PA 08 059 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R21) Apply for PA 08 060 Funding Number: PA 08 060 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Extramural Associates Research Development Award (EARDA) (G11) Apply for PAR 08 096 Funding Number: PAR 08 096 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R01) Apply for PA 08 099 Funding Number: PA 08 099 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 06 342", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.